HONG KONG – Alexion Pharmaceuticals Inc.'s blockbuster drug, Soliris (eculizumab), was granted a rapid approval by China's drug regulator, the National Medical Products Administration (NMPA, formerly CFDA), for treating paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).